Karel Švojgr

1.3k total citations
16 papers, 154 citations indexed

About

Karel Švojgr is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Ophthalmology. According to data from OpenAlex, Karel Švojgr has authored 16 papers receiving a total of 154 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 4 papers in Pulmonary and Respiratory Medicine and 4 papers in Ophthalmology. Recurrent topics in Karel Švojgr's work include Ocular Oncology and Treatments (4 papers), Corneal Surgery and Treatments (3 papers) and Renal and related cancers (3 papers). Karel Švojgr is often cited by papers focused on Ocular Oncology and Treatments (4 papers), Corneal Surgery and Treatments (3 papers) and Renal and related cancers (3 papers). Karel Švojgr collaborates with scholars based in Czechia, Germany and Austria. Karel Švojgr's co-authors include Jir̆ı́ Uhlı́k, Jakub Širc, Radka Hobzová, Pavel Pochop, Tomáš Kalina, Tomáš Brdička, Václav Hořejšı́, Peter Dráber, Ondřej Štěpánek and Jan Hraběta and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and International Journal of Pharmaceutics.

In The Last Decade

Karel Švojgr

13 papers receiving 152 citations

Peers

Countries citing papers authored by Karel Švojgr

Since Specialization

Citations

This map shows the geographic impact of Karel Švojgr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karel Švojgr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karel Švojgr more than expected).

Fields of papers citing papers by Karel Švojgr

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karel Švojgr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karel Švojgr. The network helps show where Karel Švojgr may publish in the future.

Co-authorship network of co-authors of Karel Švojgr

This figure shows the co-authorship network connecting the top 25 collaborators of Karel Švojgr. A scholar is included among the top collaborators of Karel Švojgr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karel Švojgr. Karel Švojgr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Long-term off-label MAPK inhibitor therapy in children with severe/refractory Langerhans cell histiocytosis: An international observational study of 277 cases. 2025 ·Journal of Clinical Oncology ·Jean Donadieu, D. A. Evseev, Caroline Hutter, Ф. Пегораро, Elena Sieni, Olga Slater, Cor van den Bos, (unknown), Myriam Weyl Ben Arush, Thomas Lehrnbecher, Itziar Astigarraga, (unknown), Michael Maschan, (unknown), Karel Švojgr, Islam Amine Larabi, (unknown), Jan‐Inge Henter, Sébastien Heritier, Milen Minkov	0
2	The Role of Cryotherapy in Vitreous Concentrations of Topotecan Delivered by Episcleral Hydrogel Implant 2022 ·Pharmaceutics ·(unknown), Radka Hobzová, Jakub Širc, Jir̆ı́ Uhlı́k, (unknown), Karel Švojgr, (unknown), (unknown), Ondřej Slanař, Martin Šíma, Igor Kozák, Pavel Pochop	3
3	Is There a Higher Incidence of Sporadic Renal Angiomyolipoma in Childhood Cancer Survivors? 2021 ·Clinical Epidemiology ·Jarmila Kruseová, (unknown), (unknown), Karel Švojgr, Petr Hošek, (unknown), Martin Kynčl, Tomáš Eckschlager	2
4	Hydrogel implants for transscleral diffusion delivery of topotecan: In vivo proof of concept in a rabbit eye model 2021 ·International Journal of Pharmaceutics ·Radka Hobzová, (unknown), Pavel Pochop, Jir̆ı́ Uhlı́k, (unknown), Karel Švojgr, Jan Hraběta, (unknown), (unknown), Jakub Širc	7
5	2‐Hydroxyethyl Methacrylate Hydrogels for Local Drug Delivery: Study of Topotecan and Vincristine Sorption/Desorption Kinetics and Polymer‐Drug Interaction by ATR‐FTIR Spectroscopy 2021 ·Macromolecular Chemistry and Physics ·(unknown), Radka Hobzová, Miroslava Trchová, Karel Švojgr, (unknown), Pavel Pochop, Jir̆ı́ Uhlı́k, Jakub Širc	19
6	Gastric tumors in children: single-center study with emphasis on treatment of repeated recurrence 2020 ·Pediatric Surgery International ·(unknown), J Šnajdauf, (unknown), Barbora Frýbová, Karel Švojgr, Zdeněk Linke, Vladimír Mixa, Roman Kodet, Martin Kynčl, Michal Rygl	3
7	Hydrogel implants for transscleral drug delivery for retinoblastoma treatment 2019 ·Materials Science and Engineering C ·(unknown), Radka Hobzová, Jakub Širc, (unknown), Jan Hraběta, Karel Švojgr, Pavel Pochop, (unknown), Jarmila Jedelská, Udo Bakowsky, Jir̆ı́ Uhlı́k	37
8	Retinoblastoma 2016 ·Karel Švojgr	0
9	Fanconi Anemia, Complementation Group D1 Caused by Biallelic Mutations of BRCA2 Gene – Case Report 2016 ·Klinicka onkologie ·Alena Puchmajerová, Karel Švojgr, (unknown), Eva Macháčková, David Sumerauer, Petr Smíšek, Roman Kodet, Martin Kynčl, Anna Křepelová, Lenka Foretová	1
10	Hepatoblastoma, Etiology, Case Reports 2016 ·Klinicka onkologie ·Alena Puchmajerová, Anna Křepelová, (unknown), (unknown), Ivan Balaščák, (unknown), Karel Švojgr, (unknown), Martin Kynčl, Aleš Vícha, Milan Maçek	3
11	Fanconi anemia with biallelic FANCD1/BRCA2 mutations – Case report of a family with three affected children 2015 ·European Journal of Medical Genetics ·Karel Švojgr, David Sumerauer, Alena Puchmajerová, Aleš Vícha, Ondřej Hrušák, K Michalová, Josef Mališ, Petr Smíšek, Martin Kynčl, (unknown), Eva Macháčková, (unknown), (unknown), (unknown), Roman Kodet, Jan Starý	12
12	Nephroblastoma – 30-Years Period of its Treatment in the University Hospital Motol, Prague 2013 ·Klinicka onkologie ·Josef Mališ, Karel Švojgr, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Daniela Kodetová, Běla Malinová, (unknown), J Šnajdauf, Jan Starý	0
13	The adaptor protein NTAL enhances proximal signaling and potentiates corticosteroid-induced apoptosis in T-ALL 2012 ·Experimental Hematology ·Karel Švojgr, Tomáš Kalina, Veronika Kanderová, (unknown), Tomáš Brdička, Jan Zuna	7
14	Ikaros (IKZF1) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood BCR/ABL‐negative acute lymphoblastic leukemia 2012 ·Pediatric Blood & Cancer ·(unknown), Ester Mejstříková, Petra Dörge, Barbara Meissner, Olga Zimmermannová, Karel Švojgr, Martin Stanulla, Gunnar Cario, Martin Schrappe, Jan Starý, Ondřej Hrušák, Jan Trka, Eva Froňková	19
15	Regulation of Src Family Kinases Involved in T Cell Receptor Signaling by Protein-tyrosine Phosphatase CD148 2011 ·Journal of Biological Chemistry ·Ondřej Štěpánek, Tomáš Kalina, Peter Dráber, (unknown), Karel Švojgr, Pavla Angelisová, Václav Hořejšı́, Arthur Weiss, Tomáš Brdička	32
16	Adaptor molecules expression in normal lymphopoiesis and in childhood leukemia 2009 ·Immunology Letters ·Karel Švojgr, Tatiana Burjanivová, Martina Vašková, Tomáš Kalina, Jan Starý, Jan Trka, Jan Zuna	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact